Owkin Co-founder argues a refocusing AI in medical research at 40th J.P. Morgan Healthcare Conference
Thomas Clozel, co-founder and CEO of AI for medical research startup Owkin, will present at the 40th Annual J.P. Morgan Healthcare Conference at 10am EST on Monday 10th January.
Thomas will say that the COVID-19 pandemic revealed that some current AI approaches to drug discovery have limitations. He will argue that AI must not be the end product of research – and that we must now focus on using AI as an interactive tool that biologists, developers and physicians can use to co-create new knowledge.
Thomas will share how Owkin’s technology is revolutionizing drug discovery and development by focusing on unlocking the potential that lies within patient data, allowing researchers to improve the more fundamental understanding of disease mechanisms.
Following Owkin becoming a unicorn in 2021, Thomas will share Owkin’s five priorities for 2022:
🧑💻 Creating the world’s referent federated patient database on the single-cell resolution 🧑💻
🤝 Beginning one new strategic alliance with current pharmaceutical partners 🤝
💊 Using our end-to-end platform for drug discovery and development with the 10 largest biopharma companies 💊
🧬 Making breakthrough discoveries on genotype/phenotype with our platform in three unmet medical needs 🧬
🏢 Break pharma silos with more federated pharma consortia projects like MELLODDY and OPTIMA 🏢
About Owkin
Owkin is a French-American startup that specializes in AI and federated learning for medical research.
Owkin was founded by Thomas Clozel MD, a clinical hemo-oncologist, and Gilles Wainrib, an academic researcher in biomedical AI, in 2016. It became a unicorn in November through a $180 million investment from Sanofi.
Owkin has published groundbreaking research at the frontier of AI and medicine in Nature Medicine, Nature Communications and Hepatology, among other leading journals. Owkin works with the most prominent cancer centers and pharmaceutical companies in Europe and the US.
The Owkin Platform connects life science companies with world-class academic researchers and hospitals to share deep medical insights for drug discovery and development. Using federated learning and breakthrough collaborative AI technology, Owkin enables its partners to unlock siloed single-cell resolution patient datasets while protecting patient privacy and securing proprietary data. Through sharing high-value insights, the company powers unprecedented collaboration to improve patient outcomes.
For more information, visit Owkin.com and follow @OWKINscience on Twitter.
About Owkin
Owkin is the first end-to-end AI biotech company on a mission to understand complex biology and ensure every patient gets the right treatment.
We identify precision therapeutics, de-risk and accelerate clinical trials, and develop diagnostics using AI trained on world-class patient data through privacy-enhancing technologies. We merge wet lab experiments with advanced AI techniques to create a powerful feedback loop for accelerated discovery and innovation in oncology, cardiovascular disease, and immunity and inflammation.
Owkin also founded MOSAIC, the world’s largest spatial multi-omics atlas for cancer research across nine cancer indications.
Owkin has raised over $300 million through investments from leading biopharma companies, including Sanofi and BMS, and venture funds like F-Prime, GV and Bpifrance, among others.
